companydata.dkHemab ApS: Financial statements 2022
CVR: 40837590
Hemab ApS (CVR 40837590) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -156,407,000 compared with DKK -35,163,000 the year before. Equity amounted to DKK 6,101,000. The solvency ratio was 18.5%. The company had 10 employees in the financial year.
- Profit/Loss
- -156,407,000 kr.
- Equity
- 6,101,000 kr.
- Total Assets
- 32,916,000 kr.
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -156.4 mio. | 6.1 mio. | 10 |
| 2021 | - | - | -35.2 mio. | 68 mio. | 3 |
Keep an eye on Hemab ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Hemab ApS has published its annual report for 2021. The net result was DKK -35,163,000.
As of January 10, 2022, Jørgen Søberg Petersen has joined the board of directors of Hemab ApS.
As of January 10, 2022, Linda Catharina Bain has joined the board of directors of Hemab ApS.
As of January 10, 2022, John Michael Maraganore has joined the board of directors of Hemab ApS.
As of January 10, 2022, Benny Sørensen is registered as adm. dir. of Hemab ApS.
As of January 9, 2022, Jørgen Søberg Petersen has left the board of directors of Hemab ApS.
About Hemab ApS
Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The company is owned by Hemab Therapeutics Holdings, Inc.. Equity amounted to DKK 196,000.